title: Influence of metoprolol CR/ZOK on plasminogen activator inhibitor (PAI-1) in man: a pilot study.
abstract: Recent primary and secondary preventive trials have shown that long-term metoprolol therapy reduces the risk of acute cardiovascular complications. To test whether part of this beneficial long-term effect may be due to effects on the fibrinolytic system, three pilot studies were performed; two in healthy individuals, and one in patients with mild hypertension or uncomplicated atrial fibrillation. The effect of metoprolol CR/ZOK (controlled release) 100-200 mg daily, on plasminogen activator inhibitor activity (PAI-1) in plasma was measured. In addition serum triglycerides and orosomucoid were analyzed. All the individuals were included in double-blind placebo controlled cross-over trials with treatment periods ranging from 4 days to 3 weeks. During metoprolol therapy PAI-1 values were reduced, while orosomucoid and triglyceride levels were unchanged. A linear inverse correlation was found between fibrinolysis and PAI-1 activity in plasma, indicating that PAI-1 activity serves as an indicator of fibrinolysis. PAI-1 activity and triglycerides were significantly correlated during placebo and metoprolol therapy. In conclusion, our results in these pilot studies suggest that metoprolol enhances fibrinolytic activity as seen by reduced PAI-1 activity. These results should be further confirmed and put into relation of clinical effects of the therapy.
authors.affiliation: Cardiovascular Research AB Hässle, Mölndal, Sweden.
authors.forename: A C
authors.initials: AC
authors.lastname: Teger-Nilsson
authors.forename: C
authors.initials: C
authors.lastname: Dahlöf
authors.forename: E
authors.initials: E
authors.lastname: Haglund
authors.forename: C
authors.initials: C
authors.lastname: Hedman
authors.forename: G
authors.initials: G
authors.lastname: Olsson
authors.forename: B
authors.initials: B
authors.lastname: Ablad
mesh_terms: D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged; D009961:Orosomucoid / Q000378:metabolism; D010865:Pilot Projects; D015849:Plasminogen Inactivators / Q000378:metabolism*; D011446:Prospective Studies; D014280:Triglycerides / Q000097:blood
chemical_list: D003692:Delayed-Action Preparations; D009961:Orosomucoid; D015849:Plasminogen Inactivators; D014280:Triglycerides; D008790:Metoprolol